Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors

A pharmaceutical formulation presented in unit dose form comprising

• the compound of formula
• as an active ingredient,
• wherein said active ingredient s present within said unit dose form in an amount from 70 mg to 700 mg.